Drug repurposing of rimantadine for treatment of cancer

Pharm Pat Anal. 2023 Nov 20. doi: 10.4155/ppa-2023-0019. Online ahead of print.


Repurposing of approved drugs allows strong savings in time and investment. Rimantadine is an FDA-approved drug for prevention and treatment of influenza A infection. Patent US2021330605 describes the use of rimantadine, an adamantane derivative, for the treatment of melanoma, breast cancer and head and neck squamous cell carcinoma. Rimantadine inhibited proliferation of cell lines of melanoma, breast cancer, and head and neck squamous cell carcinoma, increased the survival of mice injected with cancer cell lines and restores the expression of MHC class I. Rimantadine has the potential to be used successfully in the treatment of head and neck squamous cell carcinoma.

Keywords: HPV16-E7; MHC I; anti-PD-L1; drug repurposing; head and neck squamous cell carcinoma; rimantadine.